Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nonresponders to full dose PEG-IFN/RBV therapy~* Liver biopsy within the last 2 year~Exclusion Criteria:~* Intolerance to one of the study drugs~* Coinfection with HIV/HBV

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- on treatment nonresponders (Type: EXPERIMENTAL): naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
- Nonresponders to previous antiviral combination therapy (Type: EXPERIMENTAL): Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).